Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05664880 · ClinicalTrials.gov registry record · Early Phase 1

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

A Early Phase 1 study of Chronic Pancreatitis, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05664880 is a Early Phase 1 study of Chronic Pancreatitis that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 24 participants, below the 688-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05664880, a Early Phase 1 study of Chronic Pancreatitis, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Paricalcitol

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-06-01
Est. Completion 2026-12
Phase Early Phase 1

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT05664880

The ClinicalTrials.gov registry entry for NCT05664880 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 688-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (97% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05664880 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05664880 about?

NCT05664880 is a clinical study titled "A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis". The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

What is the current status of trial NCT05664880?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-06-01. Estimated completion is 2026-12.

What conditions does trial NCT05664880 study?

This clinical trial studies the following conditions: Chronic Pancreatitis.

What interventions are being tested in trial NCT05664880?

The interventions under investigation include: Placebo (DRUG), Paricalcitol (DRUG).

Who is sponsoring clinical trial NCT05664880?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05664880 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.